Alvotech has indicated that it has little concern for now considering Merck & Co’s plan to shift manufacturing for its $25bn Keytruda (pembrolizumab) immuno-oncology juggernaut from batch to continuous perfusion, owing to the Icelandic firm’s previous investments in its own manufacturing.
As Alvotech presented its fourth-quarter and annual financial results, one analyst asked during the firm’s earnings call whether Merck’s move “could result in any regulatory delays to biosimilar launch in light of their recent